☆ 4.7 Letter

Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by Kaklamanos et al

ANNALS OF THE RHEUMATIC DISEASES (2023)

Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'

Aimilios Kaklamanos et al.

ANNALS OF THE RHEUMATIC DISEASES (2023)

添加到收藏夹

Article Medicine, General & Internal

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

Carlos Salama et al.

Summary: Among hospitalized patients with Covid-19 pneumonia not on mechanical ventilation, tocilizumab reduced the risk of progression to mechanical ventilation or death, but did not improve overall survival. There were no new safety concerns identified.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

Anthony C. Gordon et al.

Summary: Interleukin-6 receptor antagonists tocilizumab and sarilumab were found to improve outcomes, including survival, in critically ill patients with Covid-19 receiving organ support in ICUs according to an ongoing international trial. The efficacy of these treatments has been confirmed, with patients benefiting from the therapy.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Rheumatology

COVID-19-induced hyperinflammation, immunosuppression, recovery and survival: how causal inference may help draw robust conclusions

Robert B. M. Landewe et al.

Summary: The CHIC study compares immunosuppressive treatment with supportive treatment in COVID-19 patients with hyperinflammation. Results show that immunosuppressive treatment leads to significant improvement in 14-day outcomes and 30-day/90-day survival rates, with CRP-mediated effects playing a crucial role in patient recovery.

RMD OPEN (2021)

添加到收藏夹

Article Rheumatology

Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study

Sofia Ramiro et al.

ANNALS OF THE RHEUMATIC DISEASES (2020)

添加到收藏夹

Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by Kaklamanos et al

相关参考文献

Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

COVID-19-induced hyperinflammation, immunosuppression, recovery and survival: how causal inference may help draw robust conclusions

Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study

导出引文

分享论文